Medical Specialty >> Gynecology
PTSD Can Take Heavy Toll on Hearts of Female Vets
4:00 PM CDT.
Read article
- When Arteries Narrow, Chest Pain Can Come Earlier for Women Than Men
- Gene Tests May Guard Older Breast Cancer Patients Against Other Tumors
- Endometriosis Risk Can Be Predicted in Young Girls: Study
- Maria Shriver Sounds the Alarm on Women and Alzheimer’s
JOURNAL UPDATE
Pregnancy-Related Factors Linked to Risk for Psychosis in Child
7:00 PM CDT. Review and meta-analysis ID 30 factors that raise risk for child psychosis, five factors that protect- Moderate Maternal Fish Intake May Aid Child Metabolic Health
- Physician’s Briefing Weekly Coronavirus Roundup
- Three Neonates Born to Mothers With COVID-19 ID’d as Positive
MONTHLY JOURNAL SUMMARY
February 2020 Briefing - OBGYN & Women’s Health
March 02, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
